Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)

INTRODUCTION: Glucagon-like peptide (GLP)-1 receptor agonists exert potent hypoglycemic effects in patients with type 2 diabetes (T2D) in a blood glucose concentration-dependent manner. Once-weekly subcutaneous administration of the GLP-1 receptor agonist semaglutide has beneficial effects on glycem...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomoto, Hiroshi, Oba-Yamamoto, Chiho, Takahashi, Yuka, Takeuchi, Jun, Nagai, So, Yokoyama, Hiroki, Taneda, Shinji, Kurihara, Yoshio, Aoki, Shin, Kameda, Hiraku, Cho, Kyu Yong, Nakamura, Akinobu, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947125/
https://www.ncbi.nlm.nih.gov/pubmed/33491111
http://dx.doi.org/10.1007/s13300-020-00986-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947125/
https://www.ncbi.nlm.nih.gov/pubmed/33491111
http://dx.doi.org/10.1007/s13300-020-00986-9

Ejemplares similares